Search Results

Lutetium

• Source: Funk & Wagnalls New World Encyclopedia. 2018, 1p.

Record details

Neoadjuvant lutetium PSMA, the TIME and immune response in high-risk localized prostate cancer.

• Authors : Eapen RS; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia. .; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia. .

Subjects: Prostatic Neoplasms*/Prostatic Neoplasms*/Prostatic Neoplasms*/therapy ; Prostatic Neoplasms*/Prostatic Neoplasms*/Prostatic Neoplasms*/immunology ; Prostatic Neoplasms*/Prostatic Neoplasms*/Prostatic Neoplasms*/pathology

• Source: Nature reviews. Urology [Nat Rev Urol] 2024 Nov; Vol. 21 (11), pp. 676-686. Date of Electronic Publication: 2024 Aug 07.Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101500082 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Short-Term Biological Toxicity Prediction of [ 177 Lu]Lutetium-Oxodotreotide: An Original Retrospective Analysis.

• Authors : Dubois J; Department of Radiopharmacy, La Timone University Hospital, CERIMED, Aix-Marseille University, Marseille, France.; Department of Radiopharmacy, Montpellier University Hospital, Montpellier University, Montpellier, France.

Subjects: Neuroendocrine Tumors*/Neuroendocrine Tumors*/Neuroendocrine Tumors*/radiotherapy ; Neuroendocrine Tumors*/Neuroendocrine Tumors*/Neuroendocrine Tumors*/pathology ; Neuroendocrine Tumors*/Neuroendocrine Tumors*/Neuroendocrine Tumors*/drug therapy

• Source: Cancer biotherapy & radiopharmaceuticals [Cancer Biother Radiopharm] 2024 Jun; Vol. 39 (5), pp. 381-389. Date of Electronic Publication: 2024 Apr 24.Publisher: Mary Ann Liebert, Inc Country of Publication: United States NLM ID: 9605408 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Lutetium Texaphyrin-Celecoxib Conjugate as a Potential Immuno-Photodynamic Therapy Agent.

• Authors : An J; Department of Chemistry, Korea University, Seoul 02841, Korea.; Lv KP

Subjects: Photochemotherapy* ; Photosensitizing Agents*/Photosensitizing Agents*/Photosensitizing Agents*/chemistry ; Photosensitizing Agents*/Photosensitizing Agents*/Photosensitizing Agents*/pharmacology

• Source: Journal of the American Chemical Society [J Am Chem Soc] 2024 Jul 17; Vol. 146 (28), pp. 19434-19448. Date of Electronic Publication: 2024 Jul 03.Publisher: American Chemical Society Country of Publication: United States NLM ID: 7503056 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Real-world Outcomes and Predictive Biomarkers for 177 Lutetium Prostate-specific Membrane Antigen Ligand Treatment in Metastatic Castration-resistant Prostate Cancer: A European Association of Urology Young Academic Urologists Prostate Cancer Working Group Multi-institutional Observational Study.

• Authors : Kafka M; Department of Urology, Medical University Innsbruck, Innsbruck, Austria.; Horninger A

Subjects: Prostatic Neoplasms, Castration-Resistant*/Prostatic Neoplasms, Castration-Resistant*/Prostatic Neoplasms, Castration-Resistant*/pathology ; Prostatic Neoplasms, Castration-Resistant*/Prostatic Neoplasms, Castration-Resistant*/Prostatic Neoplasms, Castration-Resistant*/radiotherapy ; Prostatic Neoplasms, Castration-Resistant*/Prostatic Neoplasms, Castration-Resistant*/Prostatic Neoplasms, Castration-Resistant*/drug therapy

• Source: European urology oncology [Eur Urol Oncol] 2024 Jun; Vol. 7 (3), pp. 421-429. Date of Electronic Publication: 2023 Aug 19.Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101724904 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Dosing lutetium Lu 177-dotatate for a hemodialysis patient.

• Authors : Taylor L; UCL Department of Renal Medicine, Royal Free Hospital, University College London, London, UK.; Meades R

Subjects: Lutetium*/Lutetium*/Lutetium*/therapeutic use ; Renal Dialysis* ; Radionuclide Imaging*

• Source: Hemodialysis international. International Symposium on Home Hemodialysis [Hemodial Int] 2024 Apr; Vol. 28 (2), pp. 247-252. Date of Electronic Publication: 2024 Mar 06.Publisher: Blackwell Pub Country of Publication: Canada NLM ID: 101093910 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Determination of lutetium density in LYSO crystals: methodology and PET detector applications.

• Authors : Thien TC; Department of Physics, National Central University, Taiwan.; Institute of Physics, Academia Sinica, Taiwan.

Subjects: Yttrium* ; Lutetium*/Lutetium*/Lutetium*/chemistry; Positron-Emission Tomography/Positron-Emission Tomography/Positron-Emission Tomography/methods

• Source: Physics in medicine and biology [Phys Med Biol] 2024 Mar 26; Vol. 69 (7). Date of Electronic Publication: 2024 Mar 26.Publisher: IOP Publishing Country of Publication: England NLM ID: 0401220 Publication Model: Electronic Cited Medium: Internet ISSN: 1361-6560

Record details

Comparison of the tolerability of 161 Tb- and 177 Lu-labeled somatostatin analogues in the preclinical setting.

• Authors : Busslinger SD; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, Villigen-PSI, 5232, Switzerland.; Mapanao AK

Subjects: Lutetium*/Lutetium*/Lutetium*/therapeutic use ; Somatostatin*/Somatostatin*/Somatostatin*/analogs & derivatives ; Somatostatin*/Somatostatin*/Somatostatin*/pharmacology

• Source: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2024 Nov; Vol. 51 (13), pp. 4049-4061. Date of Electronic Publication: 2024 Jul 24.Publisher: Springer-Verlag Berlin Country of Publication: Germany NLM ID: 101140988 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Efficacy and safety of rechallenge [ 177 Lu]Lu-PSMA-617 RLT after initial partial remission in patients with mCRPC: evaluation of a prospective registry (REALITY study).

• Authors : Rosar F; Department of Nuclear Medicine, Saarland University - Medical Center, Kirrberger Str. 100, Geb. 50, D-66421, Homburg, Germany.; Schuler J

Subjects: Dipeptides*/Dipeptides*/Dipeptides*/therapeutic use ; Dipeptides*/Dipeptides*/Dipeptides*/adverse effects ; Heterocyclic Compounds, 1-Ring*/Heterocyclic Compounds, 1-Ring*/Heterocyclic Compounds, 1-Ring*/therapeutic use

• Source: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2024 Nov; Vol. 51 (13), pp. 4151-4162. Date of Electronic Publication: 2024 Jul 15.Publisher: Springer-Verlag Berlin Country of Publication: Germany NLM ID: 101140988 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Survey of Clinical Protocols for the Use of 177 Lu-PSMA-617 in the United States.

• Authors : Kuo PH; Department of Medical Imaging, University of Arizona, Tucson, Arizona; .

Subjects: Dipeptides*/Dipeptides*/Dipeptides*/therapeutic use ; Heterocyclic Compounds, 1-Ring* ; Lutetium*

• Source: Journal of nuclear medicine technology [J Nucl Med Technol] 2024 Sep 05; Vol. 52 (3), pp. 208-211. Date of Electronic Publication: 2024 Sep 05.Publisher: Society of Nuclear Medicine Country of Publication: United States NLM ID: 0430303 Publication Model: Electronic Cited Medium: Internet

Record details